Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Leukemia, Promyelocytic, Acute 1Leukemia, Prolymphocytic, T-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 45Cyclophosphamide 38ibrutinib 22fludarabine 22acalabrutinib 21venetoclax 20zanubrutinib 17Lenalidomide 17Bendamustine Hydrochloride 17obinutuzumab 16fludarabine phosphate 14Magnetic Resonance Spectroscopy 14Cytarabine 14Specimen Handling 13CT-P10 13pirtobrutinib 12Biopsy 12glofitamab 10Etoposide 10Whole-Body Irradiation 9Vincristine 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Melphalan 7Doxorubicin 7brexucabtagene autoleucel 6Cyclosporine 6orelabrutinib 5Methotrexate 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × Lisaftoclax × 1 year × Clear all
NCT07272499 2025-12-09

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Ruijin Hospital

Phase 2 Recruiting
25 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡